Novo Nordisk’s Board Overhaul Aims to Boost U.S. Growth Amid Weight-Loss Market Challenges
Novo Nordisk, a Danish multinational specializing in diabetes and obesity therapeutics, has undergone a significant boardroom realignment in response to intensifying regulatory scrutiny and competitive pressure in the US market, where its flagship G…
4 minutes to read